Hippocratic AI Expands Life Sciences Leadership Team as Pharma and Medtech Demand for Voice AI Agents Accelerates

New senior executive hires solidify Hippocratic AI as the category leader in safe generative AI for life sciences

PALO ALTO, Calif., May 20, 2026 /PRNewswire/ -- Hippocratic AI, the global leader and pioneer of safe generative AI healthcare agents, today announced new senior executive appointments expanding its life sciences leadership team as the company scales its pharma and medtech business. The appointments — across engineering, medical affairs, commercial growth, and compliance — follow Hippocratic AI's January 2026 acquisition of Grove AI and the launch of Polaris Life Sciences 5.0, and signal the company's emergence as the industry's category-defining voice and conversational AI platform for pharma, biotech, and medtech.

Learn more: https://hippocraticai.com/lifesciences/

New senior executive hires solidify Hippocratic AI as the category leader in safe generative AI for life sciences

"Hippocratic AI is now the established voice and conversational AI platform for life sciences, and we are attracting the most senior leaders in the field," said Ahad Wahid, President, Life Sciences. "Sri, Toby, John, Himanshu, and Sulaiman together bring more than a century of operating experience across pharma, biotech, and medtech — exactly the bench required to deliver safe, compliant generative AI agents at the scale and standard our life sciences partners demand."

New Life Sciences Appointments:

With these appointments — and following the Grove AI acquisition and the launch of Polaris Life Sciences 5.0 — Hippocratic AI continues to set the bar for safe, compliant generative AI agents purpose-built for pharma, biotech, and medtech.

About Hippocratic AI

Hippocratic AI has developed the safest generative AI agents for healthcare. The company believes that generative AI has the ability to bring healthcare abundance to every person in the world. The company focuses on building non-diagnostic, patient-facing clinical AI agents and does not allow its agents to be used to prescribe or diagnose. Hippocratic AI has received a total of $404 million in funding and is backed by leading investors, including Andreessen Horowitz, General Catalyst, Kleiner Perkins, Avenir, NVIDIA's NVentures, Premji Invest, SV Angel, Google's CapitalG, and numerous health systems. Learn more at https://hippocraticai.com/.

SOURCE Hippocratic AI